Share |

Boston Foundation for Sight

 464 Hillside Avenue, Suite 205
 Needham, MA 02494
[P] (781) 7267512
[F] (781) 7267310
Tara Stepanian
 Printable Profile (Summary / Full)
EIN 04-3150037

LAST UPDATED: 05/30/2018
Organization DBA BostonSight
Former Names --
Organization received a competitive grant from the Boston Foundation in the past five years No



Mission StatementMORE »

BostonSight's mission is to improve the quality of life for patients and families worldwide by transforming the understanding, treatment and care of complex corneal disease.

Mission Statement

BostonSight's mission is to improve the quality of life for patients and families worldwide by transforming the understanding, treatment and care of complex corneal disease.

FinancialsMORE »

Fiscal Year Jan 01, 2016 to Dec 31, 2016
Projected Income $5,749,326.00
Projected Expense $6,270,094.00

ProgramsMORE »

  • --
  • 1. Prosthetic Replacement of the Ocular Surface Ecosystem

Revenue vs. Expense ($000s)

Expense Breakdown 2015 (%)

Expense Breakdown 2014 (%)

Expense Breakdown 2013 (%)

For more details regarding the organization's financial information, select the financial tab and review available comments.


Mission Statement

BostonSight's mission is to improve the quality of life for patients and families worldwide by transforming the understanding, treatment and care of complex corneal disease.

Background Statement

The Boston Foundation for Sight (BFS) is an internationally renowned not-for-profit eye healthcare organization dedicated to restoring vision and improving quality of life for our patients and their families. We strive to transform the understanding, treatment and care of complex corneal disease within the global medical community and the public at large. Since our founding in 1994, we have been innovative leaders in research and treatment of corneal conditions.
Prosthetic replacement of the ocular surface ecosystem (PROSE) is a pioneering treatment model developed by the Boston Foundation for Sight to restore vision, support healing, reduce symptoms and improve quality of life for patients suffering with complex corneal disease. PROSE vision rehabilitation uses FDA-approved (1994) custom designed and fabricated prosthetic devices to replace or augment the impaired ocular surface system function. For many of the thousands of patients with conditions such as Stevens-Johnson syndrome, chronic ocular graft-versus-host disease (GVHD), dry eye syndrome, Sjogren’s syndrome, keratoconus, pellucid marginal degeneration, ocular trauma, complications of LASIK, or complications of cornea transplantation, PROSE can be the ideal, and sometimes only, treatment capable of restoring vision and dramatically reducing symptoms such as eye pain, dry eye, blurry vision and light sensitivity.

Impact Statement

2015 Accomplishments:  More than 1,260 patients worldwide received BostonSight PROSE treatment; provided more than $523,550 in financial assistance to 161 patients in the Needham clinic and an additional $104,400 in assistance to 52 patients within the PROSE provider network; trained  two new BostonSight Clinical Fellows in to the provider network at Brooke Army Medical Center in San Antonio, TX and at University of California, San Francisco, CA; continue to work on ways to make customization more efficient.

2016 Goals 

♦ Educate

  • Increase widespread awareness and understanding of complex corneal disease through patient and public education, and professional education including post-doctoral residencies and clinical fellowships

♦ Empower

  • Build resilient community networks that empower patients and families to live well with corneal disease by enhancing the capacity for learning, support, advocacy and collective action

♦ Treat

  • Provide exemplary patient-centered care using a collaborative team treatment approach that restores vision, supports healing, reduces symptoms and improves quality of life, regardless of ability to pay

♦ Innovate

  • Conduct cutting-edge clinical research and technological innovation in the design, manufacture and application of custom prosthetic devices that replace and/or enhance the function of the ocular surface ecosystem

♦ Transform

  • Revolutionize standard of care by replicating our PROSE treatment model (prosthetic replacement of the ocular surface ecosystem) with our partners at world-class academic medical centers in the United States and abroad  

Needs Statement

Program - Financial assistance.  In order to eliminate barriers to treatment for those who are uninsured or underinsured, BostonSight provided more than $628,000 in financial aid to patients in Needham and within our domestic BostonSight Provider network.  However the aid required by our patients outstripped philanthropic gifts.
Program:  SJS Care Weeks -  An annual patient networking and outreach event dedicated to ocular treatment of survivors of Stevens Johnson Syndrome.  SJS is a life-threatening skin condition in which cell death causes the epidermis to separate from the dermis.  The syndrome is thought to be a hypersensitivity complex that affects the skin and mucous membranes.  The immune reaction can be triggered by drugs or infection.  SJS frequently causes the formation of scar tissue inside the eyelids, leading to corneal vascularization, impaired vision and a host of other ocular problems.  SJS Care Week is designed to ensure on-going treatment of this population, defraying the costs of  lodging and travel for those whom require assistance.

CEO Statement

In 2015, BostonSight provided care to more than 1,260 patients worldwide, providing financial assistance to over 16% of that population.  Each patient who walks through our doors comes with their personal story of suffering and lives severely compromised by corneal disease.  During the time they spend here, working one-on-one with a BostonSight PROSE clinician to restore their visual function, they not only regain their sight, but and then able to return home to reclaim their lives.  
We are often the last bastion of hope for people with complex corneal disease who have been in the medical system for years - trying to find the right solution - but continue to suffer.  We are fortunate to offer to these patients this haven of care and of hope.  It is a privilege to offer such amazingly high-tech and compassionate care and to change lives for the better.

Board Chair Statement


Geographic Area Served

Throughout the United States

We are located in Needham MA, eight miles west of Boston. Our patient population is largely from the United States, but also travel from as far away as Canada and Mexico.

Organization Categories

  1. Health Care - Patient & Family Support
  2. Medical Research - Eye Diseases, Blindness & Vision Impairments Research
  3. -

Independent research has been conducted on this organization's theory of change or on the effectiveness of this organization's program(s)




The Boston Foundation for Sight, a (501)(c)(3) nonprofit organization, has a clinic and research facility that employees 28 doctors and support staff with a yearly budget of over $2,000,000. It has restored the vision and/or eliminated sever occular pain for more than one thousand patients.
Budget  --
Category  --
Population Served --
Program Short-Term Success  --
Program Long-Term Success  We saw eight times the number of patients seen in 2003 with a 94% success rate.
Program Success Monitored By  --
Examples of Program Success  --

1. Prosthetic Replacement of the Ocular Surface Ecosystem

Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) is a pioneering treatment model developed by the Boston Foundation for Sight to restore vision, support healing, reduce symptoms and improve quality of life for patients suffering with complex corneal disease.
Budget  --
Category  Health Care, General/Other
Population Served US& International
Program Short-Term Success  PROSE treatment has significantly improved visual acuity and visual function in patients with corneal ectasia, irregular astigmatism and ocular surface disease who have failed convention therapies.  Treatment has a high success rate when measured by ability to achieve satisfactory fit, impact on visual acuity and 6 month data on both continued wear and impact on visual function. 
Program Long-Term Success  BostonSight PROSE Treatment is an innovative and integrated treatment model for complex corneal disease developed by Boston Foundation for Sight (BostonSight).  It uses FDA approved (1994) custom designed and manufactured prosthetic devices to replace or support impaired ocular surface function in cases of "distorted corneal surface or certain ocular surface disorders".  We are committed to helping patients suffering with corneal disease so that their lives are no longer lost to constant eye pain or limited by poor visual function.  Since our inception, we have helped over 5000 patients worldwide.  Estimated USA candidates for PROSE treatment are 57,000.
Program Success Monitored By  Of 199 patients seen, mean improvement NEI VFQ-25 = 22 points at 6 months; 19 points at 5 years.  
Examples of Program Success 

Patient Story:  Susan P.

Dry eye began affecting Susan’s life in her mid-50’s. “My eyes were dry and sore all the time, and very sensitive to sunlight, and it just kept getting worse. It felt like my eyes had a headache all the time.” When she arrived in Needham for BostonSight® PROSE treatment, Susan’s eye condition had worsened to the point that she couldn’t tolerate bright light, and was unable use the computer, read, or drive a car.

A busy professional who juggles several business ventures, and also volunteers with her certified therapy dog in her local school system, Susan was thrilled when she learned that PROSE might be the answer she was looking for. “I had spent a ton of money on eye drops, expensive sunglasses, and many different doctors. When I heard about PROSE, I would have gone anywhere to try it. Lucky me, it was practically in my own backyard,” said the coastal Massachusetts resident.

“PROSE treatment was a miracle for me. Everyone at BostonSight was pleasant, patient, and soothing,” remembers Susan.  Susan particularly enjoyed the community kitchen, where she met patients who had traveled there from around the world. “It was beautiful to be able to experience all of those people able to see again.”

Now able to resume her active life, Susan has some advice for anyone going through their own personal healthy journey. “Many people don’t have the time or perseverance to keep researching and looking for a solution. But you have to be your own best advocate. When you have a health problem, don’t give up! There is always a solution.”


CEO/Executive Director/Board Comments



CEO/Executive Director Mr. Gene Guselli
CEO Term Start Apr 2016
CEO Email
CEO Experience

Gene was co-Founder, President, and CEO of InfoMedics, Inc., a pharmaceutical company service provider of the leading global Software as a Service (SaaS) platform for the collection and analysis of patient generated health data used by clinicians to remotely manage patients. He orchestrated the sale of InfoMedics to Physicians Interactive, a digital healthcare marketing company owned by Merck. Gene became the President of Global Medical and Analytic Services for Physicians Interactive.

As co-Founder and CEO of Private Healthcare Systems, Inc., a privately held consortium of commercial healthcare insurance companies, Gene led the organization to become the largest National Preferred Provider Organization (PPO) in the US with five million members.

Gene served as Vice President for Global Health Strategy for Mobiquity, Inc., a leading global healthcare digital/mobile professional services company. He has also held Director positions at Boston Medical Center and New York City Health and Hospitals Corporation.

Additionally, Gene has worked as a Strategic Independent Consultant to multiple global life sciences, consumer health, and payer/provider clients, including: Partners Healthcare, the Center for Connected Health (CCH), Indegene Healthcare, TEVA Pharmaceuticals, Habitworks, Inc., IHopeNetworks, Zampeer, Inc., Cambridge Sound Management, and Stallergenes Pharmaceutical Company.

Co-CEO --
Co-CEO Term Start --
Co-CEO Email --
Co-CEO Experience --

Former CEOs and Terms

Name Start End
Mr. Gene A. Bonte MBA May 2010 Apr 2016
Mr. Gary F. Gut MBA Apr 2009 Apr 2010

Senior Staff

Name Title Experience/Biography
-- -- --


Award Awarding Organization Year
-- -- --


Affiliation Year
-- --
Member of state association of nonprofits? No
Name of state association --

External Assessments and Accreditations

External Assessment or Accreditation Year
-- --



CEO/Executive Director/Board Comments


Foundation Comments


Staff Information

Number of Full Time Staff 33
Number of Part Time Staff 2
Number of Volunteers 2
Number of Contract Staff 2
Staff Retention Rate % 85%

Staff Demographics

Ethnicity African American/Black: 2
Asian American/Pacific Islander: 1
Caucasian: 23
Hispanic/Latino: 5
Native American/American Indian: 0
Other: 2
Other (if specified): South East Asian
Gender Female: 22
Male: 10
Not Specified 0

Plans & Policies

Organization has Fundraising Plan? Under Development
Organization has Strategic Plan? Under Development
Years Strategic Plan Considers --
Management Succession Plan --
Business Continuity of Operations Plan --
Organization Policies And Procedures Under Development
Nondiscrimination Policy Under Development
Whistle Blower Policy Yes
Document Destruction Policy Yes
Directors and Officers Insurance Policy --
State Charitable Solicitations Permit Yes
State Registration --

Risk Management Provisions


Reporting and Evaluations

Management Reports to Board? Yes
CEO Formal Evaluation and Frequency Yes Annually
Senior Management Formal Evaluation and Frequency Yes Annually
Non Management Formal Evaluation and Frequency Yes Annually


Board Chair Mr. Gary Knaak
Board Chair Company Affiliation Content Central/Partners + Napier
Board Chair Term June 2014 - June 2017
Board Co-Chair --
Board Co-Chair Company Affiliation --
Board Co-Chair Term -

Board Members

Name Company Affiliations Status
Ms. Pamela J. Anderson Esq Clarkin & Phillips, PC Voting
Mr. Eugene A. Bonte Retired Exofficio
Mr. Mark Ealey MuLantix LLC Voting
Mr. Gene Guselli BostonSight, President and CEO Voting
Mr. Andrew Hirsch MBA BIND Therapeutics Voting
Ms. Beverly R. Johnston Community Volunteer Voting
Mr. Michael Kane MBA Kane Consulting Group Voting
Mr. Gary Knaak Partners + Napier Voting
Ms. Barbara Joyce McNeil MD, PhD Ridley Watts Professor, Harvard Medical School Voting
Mr. Michael B. Raizman MD Ophthalmic Consultants of Boston Voting
Mr. Clifford Scott OD, MPH New England College of Optometry Voting
Ms. Kathleen "Kate" Weingarten MBA, CFA, MPA Community Volunteer Voting

Constituent Board Members

Name Company Affiliations Status
-- -- --

Youth Board Members

Name Company Affiliations Status
-- -- --

Advisory Board Members

Name Company Affiliations Status
-- -- --

Board Demographics

Ethnicity African American/Black: 0
Asian American/Pacific Islander: 0
Caucasian: 12
Hispanic/Latino: 0
Native American/American Indian: 0
Other: 0
Other (if specified): 0
Gender Female: 4
Male: 8
Not Specified 0

Board Information

Board Term Lengths 3
Board Term Limits --
Board Meeting Attendance % --
Written Board Selection Criteria Under Development
Written Conflict Of Interest Policy Under Development
Percentage of Monetary Contributions 100%
Percentage of In-Kind Contributions 0%
Constituency Includes Client Representation Yes

Standing Committees

  • Audit
  • Board Governance
  • Development / Fund Development / Fund Raising / Grant Writing / Major Gifts
  • Finance
  • Membership

CEO/Executive Director/Board Comments


Foundation Comments



Revenue vs. Expense ($000s)

Expense Breakdown 2015 (%)

Expense Breakdown 2014 (%)

Expense Breakdown 2013 (%)

Fiscal Year Jan 01, 2016 to Dec 31, 2016
Projected Income $5,749,326.00
Projected Expense $6,270,094.00
Form 990s

2015 990

2014 990

2013 990

2012 990

Audit Documents

2015 Audited Financials

2014 Audited Financials

2013 Audited Financials

IRS Letter of Exemption

IRS Letter of Determination

Prior Three Years Total Revenue and Expense Totals

Fiscal Year 2015 2014 2013
Total Revenue $5,808,573 $6,125,032 $6,922,879
Total Expenses $5,930,480 $6,263,515 $6,325,719

Prior Three Years Revenue Sources

Fiscal Year 2015 2014 2013
Foundation and
Corporation Contributions
-- -- --
Government Contributions $0 $0 $0
    Federal -- -- --
    State -- -- --
    Local -- -- --
    Unspecified -- -- --
Individual Contributions $393,538 $366,441 $446,939
Indirect Public Support -- -- --
Earned Revenue $5,247,292 $5,540,494 $6,094,040
Investment Income, Net of Losses -- $18 $393
Membership Dues -- -- --
Special Events -- -- --
Revenue In-Kind -- $143,137 $239,761
Other $167,743 $74,942 $141,746

Prior Three Years Expense Allocations

Fiscal Year 2015 2014 2013
Program Expense $4,237,203 $4,279,321 $4,099,438
Administration Expense $1,470,588 $1,549,094 $1,804,395
Fundraising Expense $222,689 $435,100 $421,886
Payments to Affiliates -- -- --
Total Revenue/Total Expenses 0.98 0.98 1.09
Program Expense/Total Expenses 71% 68% 65%
Fundraising Expense/Contributed Revenue 57% 119% 94%

Prior Three Years Assets and Liabilities

Fiscal Year 2015 2014 2013
Total Assets $4,501,116 $5,251,163 $5,190,420
Current Assets $4,092,857 $4,741,355 $4,536,643
Long-Term Liabilities $0 $0 $0
Current Liabilities $384,476 $1,012,616 $813,390
Total Net Assets $4,116,640 $4,238,547 $4,377,030

Prior Three Years Top Three Funding Sources

Fiscal Year 2015 2014 2013
1st (Source and Amount) -- --
-- --
-- --
2nd (Source and Amount) -- --
-- --
-- --
3rd (Source and Amount) -- --
-- --
-- --

Financial Planning

Endowment Value --
Spending Policy N/A
Percentage(If selected) --
Credit Line Yes
Reserve Fund Yes
How many months does reserve cover? --

Capital Campaign

Are you currently in a Capital Campaign? No
Capital Campaign Purpose --
Campaign Goal --
Capital Campaign Dates -
Capital Campaign Raised-to-Date Amount --
Capital Campaign Anticipated in Next 5 Years? --

Short Term Solvency

Fiscal Year 2015 2014 2013
Current Ratio: Current Assets/Current Liabilities 10.65 4.68 5.58

Long Term Solvency

Fiscal Year 2015 2014 2013
Long-term Liabilities/Total Assets 0% 0% 0%

CEO/Executive Director/Board Comments


Foundation Comments

Financial summary data in charts and graphs are per the organization's audited financials. Contributions from foundations and corporations are listed under individuals when the breakout was not available.


Other Documents

No Other Documents currently available.


The Impact tab is a section on the Giving Common added in October 2013; as such the majority of nonprofits have not yet had the chance to complete this voluntary section. The purpose of the Impact section is to ask five deceptively simple questions that require reflection and promote communication about what really matters – results. The goal is to encourage strategic thinking about how a nonprofit will achieve its goals. The following Impact questions are being completed by nonprofits slowly, thoughtfully and at the right time for their respective organizations to ensure the most accurate information possible.

1. What is your organization aiming to accomplish?


2. What are your strategies for making this happen?


3. What are your organization’s capabilities for doing this?


4. How will your organization know if you are making progress?


5. What have and haven’t you accomplished so far?